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Abstract
Familial partial lipodystrophy is an autosomal dominant disease caused by mutations of the LMNA gene encoding alternatively spliced
lamins A and C. Abnormal distribution of body fat and insulin resistance characterize the clinical phenotype. In this study, we analyzed
primary fibroblast cultures from a patient carrying an R482L lamin A/C mutation by a morphological and biochemical approach.
Abnormalities were observed consisting of nuclear lamin A/C aggregates mostly localized close to the nuclear lamina. These aggregates
were not bound to either DNA-containing structures or RNA splicing intranuclear compartments. In addition, emerin did not colocalize with
nuclear lamin A/C aggregates. Interestingly, emerin failed to interact with lamin A in R482L mutated fibroblasts in vivo, while the
interaction with lamin C was preserved in vitro, as determined by coimmunoprecipitation experiments. The presence of lamin A/C nuclear
aggregates was restricted to actively transcribing cells, and it was increased in insulin-treated fibroblasts. In fibroblasts carrying lamin A/C
nuclear aggregates, a reduced incorporation of bromouridine was observed, demonstrating that mutated lamin A/C in FPLD cells interferes
with RNA transcription.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
Familial partial lipodystrophy (FPLD, MIM 151660) is
an inherited disease caused by mutations of the LMNA gene
coding for alternatively spliced lamins A and C [1]. The
clinical phenotype of FPLD is characterized by loss of fat in
the trunk and limbs and accumulation of fat tissue in neck
and face occurring during the peripubertal phase [2]. Addi-
tionally, variable degrees of resistance to insulin action,
together with hypertriglyceridemia, may occur [2].
In FPLD, LMNA missense mutations substitute a highly
conserved arginine at position 482, or lysine at position 486
in the C-terminal globular domain of lamin A/C [1]. In the
last few years, several diseases have been associated to
lamin A/C mutations, either dominant such as FPLD, auto-
somal Emery-Dreifuss muscular dystrophy (EDMD2) [3],
dilated cardiomyopathy and conduction system disease
(CMD-CD) [4], and limb girdle muscular dystrophy 1B
(LGMD 1B) [5], or recessive such as autosomal recessive
Emery-Dreifuss muscular dystrophy [6], mandibuloacral
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dysplasia [7], and Charcot-Marie Tooth neuropathy type 2
[8]. Recently, Hutchison-Gilford progeria syndrome has
been ascribed to laminopathies, as lamin A/C mutations and
nuclear defects have been found in patients [9–11]. The
increasing number of LMNA-related diseases strongly sug-
gests that lamin A/C is involved in a number of seemingly
unrelated tissue-specific functions. This hypothesis is fur-
ther supported by the well-known up-regulation of lamin
A/C expression in differentiated cells [12–16]. In the knock-
out mouse model for lamin A/C, a phenotype resembling
Emery-Dreifuss muscular dystrophy with Charcot-Marie
Tooth neuropathy-like changes has been described, while
adipose tissue and insulin sensitivity are nearly normal
[17,18].
Lamin A/C interacts with the nuclear envelope protein
emerin [19–23], the protein absent or mutated in X-linked
Emery-Dreifuss muscular dystrophy (EDMD1). Moreover,
anchorage of emerin at the nuclear rim is dependent upon
lamin A/C interaction [17]. Emerin expression and localiza-
tion are not affected in FPLD [24], while emerin binding to
lamin A/C in FPLD cells was not studied as far as direct
molecular interaction is concerned.
In this study, we analyzed lamin A/C–emerin interaction
in cultured FPLD fibroblasts from a patient carrying an
R482L mutation. Coimmunoprecipitation experiments
showed that emerin does not interact with lamin A in FPLD.
We also considered the possibility that lack of interaction
between emerin and lamin might cause redistribution of one
or both proteins in the nucleus. Altered lamin distribution
with dysmorphic budding nuclei in FPLD fibroblasts carry-
ing R482Q and R482W mutations has been reported, while
the authors did not find altered distribution of emerin in
FPLD cells [24]. In accordance with these reported data, we
never found mislocalization of emerin in R482L FPLD
fibroblasts. Nevertheless, lamin A/C was redistributed into
nuclear aggregates in a high percentage of cells, forming a
pattern not described before in FPLD.
Lamins have been implicated in many nuclear activities
including nuclear growth, DNA replication, and apoptosis
[25] and, more recently, in RNA transcription [26,27]. Ab-
normal localization of lamin A/C was previously described
in cells transfected with lamin A mutants [26,28–30] and
could be associated with alteration of the transcriptional
machinery. We checked the transcription rate of FPLD
fibroblasts and found reduced RNA polymerase II activity
in cells carrying abnormal lamin A/C aggregates.
Materials and methods
Cell culture and synchronization
Skin biopsies were obtained from FPLD patient G-9956
carrying an R482L lamin A/C mutation and from unaffected
control or EDMD2 (patient G-10877; LMNA mutation
R401C) patients following a written consent. Fibroblast
cultures were established from skin biopsy explants and
grown in D-MEM containing 10% fetal calf serum and
antibiotics. Cells at passages 10 to 15 were employed.
Accumulation of cells in G1 phase was obtained by serum
starvation of semiconfluent fibroblast cultures [31], while
synchronization of fibroblasts in the G2-M phase of the cell
cycle was obtained by demecolcine treatment (25 ng/ml for
24 h) and release [32]. G0 fibroblasts (resting cells) were
obtained by serum deprivation of confluent fibroblast cul-
tures for 7 days. All these cells along with not-synchronous
fibroblasts (NS) were subjected to methanol fixation and
double immunofluorescence staining with anti-PCNA and
anti-lamin A/C. PCNA staining (not shown) allowed us to
Fig. 1. Lamin A does not coprecipitate with emerin in R482L FPLD
fibroblasts. Emerin was immunoprecipitated from whole cell lysates of
control (C), EDMD2 (LMNA mutation R401C), and FPLD (LMNA muta-
tion R482L) fibroblasts. The immuno-complexes were separated by SDS-
PAGE followed by immunoblotting with anti-emerin and anti-lamin A/C
antibodies. Immunoprecipitation with anti-emerin antibody is shown in the
left panel; immunoblotting of whole lysastes with anti-lamin A/C and
anti-emerin antibody is shown in the middle panel; immuno precipitation
of a FPLD lysate with anti-lamin A/C antibody is shown in the right panel.
Molecular weight markers are indicated in kDa.
Fig. 2. Structural abnormalities of the nuclei in R482L FPLD cells. (A) Control nuclei showed lamin A/C and lamin B staining at the nuclear rim. (B) Lamin
A/C nuclear aggregates are detected in 15–20% of FPLD fibroblast nuclei. (C) In FPLD nuclei, lamin B is absent from the blebbed areas (*) in which lamin
A/C organization is also altered. A nucleus carrying both nuclear lamin A/C aggregates and anomalous distribution of lamin B is shown. Bar, 10 m.
Fig. 3. Emerin and lamin A/C do not colocalize to nuclear lamin A/C aggregates in R482L FPLD cells. Control fibroblasts are shown in A, B, and C. EDMD2
fibroblasts are shown in D, E, and F: nuclear lamin A/C aggregates are not observed in EDMD2 nuclei, while nuclear lamina abnormalities can be detected
in these cells as well as in FPLD fibroblasts (Fig. 2). For FPLD fibroblasts (G–I) different focal planes are shown: pictures obtained at the nuclear lamina
plane are shown in G, H, and I; pictures obtained at the equatorial plane of the nucleus are shown in G, H, and I. As shown in G and I (arrows), lamin
A/C nuclear aggregates are mostly observed at the nuclear lamina level, while just a few aggregates are detected at the middle plane of the nucleus, i.e., at
internal nuclear sites (G, I). No aggregates appear in anti-emerin staining (H, H) Bar, 10 m.
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Fig. 4. Electron microscopy analysis of R482L FPLD fibroblast nuclei. Alterations of the chromatin pattern were observed in FPLD nuclei (A, C, D),
compared to controls (B): they consisted mainly in lack of heterochromatin at the nuclear periphery, close to the nuclear lamina (A, C, D) (arrows).
Detachment of heterochromatin from the nuclear lamina was also observed (A, arrowhead). Nuclear pores were generally absent in the areas corresponding
to the peripheral heterochromatin loss (D, arrows). Bars: (A, D), 0.5 m, (B, C), 1 m.
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distinguish between S-phase cells and G1 or G2 cells. The
G2/M population of synchronized fibroblasts is referred to
as G2 in the text and figure legends, as only G2 cells were
considered in our analysis of lamin A/C aggregate distribu-
tion.
Insulin treatment (10 M, Sigma) of serum-starved fi-
broblasts was performed for 4 h.
FACS analysis
To check the distribution of cells in the cell cycle, FPLD
fibroblasts and controls at 50% of confluence were retrieved
by trypsin detachment, fixed in 70% ethanol for 5 h, resus-
pended in PBS containing 5 g/ml RNase for 15 min at
37°C, washed in PBS and counter-stained with propidium
iodide. Samples were analyzed by a FACStar Plus flow
cytometer (Becton Dickinson, Palo Alto, CA) equipped
with an argon ion laser tuned at 488-nm wavelength, 50 mW
light output.
Antibodies
Anti-lamin A/C goat polyclonal antibody (Santa Cruz) or
anti-lamin A/C monoclonal antibody (Novocastra) were
used for immunofluorescence staining and for Western blot
analysis. The anti-lamin A/C monoclonal antibody was used
for the immunoprecipitation experiments. Anti-lamin A
2H10 [33] was employed for immunofluorescence staining.
Monoclonal anti-emerin and anti-lamin B2 were obtained
from Novocastra. Anti-SC35 monoclonal antibody was pur-
chased from Sigma, and anti-PCNA monoclonal antibody
from Santa Cruz. Monoclonal anti-BrdU antibody was from
BD-PharMingen. Secondary antibodies were CY3-conju-
gated anti-mouse IgG (Sigma), FITC-conjugated anti-goat
IgG (DAKO), FITC-conjugated anti-mouse IgM (Sigma),
HRP conjugated anti-mouse Ig, and anti-goat Ig (Amer-
sham-Pharmacia-Biotech).
Immunoprecipitation and Western blotting
Subconfluent cells were extracted by addition of RIPA
buffer (20 mM Tris-HCl, pH 7.0, 1% NP-40, 150 mM NaCl,
10% glycerol, 10 mM EDTA, 20 mM NaF, 5 mM sodium
pyrophosphate, 1 mM Na3VO4, 1 mM PMSF, 10 g/ml
leupeptin, 10 g/ml pepstatin) at 4°C. Precleared cell ly-
sates were incubated for 3 h with anti-emerin, or anti-lamin
A/C antibody (3 g per sample), or mouse IgG to provide
a negative control, plus 30 l of 50% (v/v) of protein A/G
agarose slurry (Santa Cruz) at 4°C with gentle rocking.
Pellets were washed twice with PBS plus 1% NP-40, twice
in TNE (10 mM Tris-Cl, pH 7.5, 100 mM NaCl, 1 mM
EDTA), and boiled in Laemmli sample buffer.
Immunoprecipitated proteins and whole cell lysates ob-
tained in RIPA buffer were subjected to Western blotting.
Samples were loaded onto 12% SDS-PAGE gel, blotted
onto nitrocellulose, and probed with specific anti-lamin A/C
or emerin antibodies or HRP-conjugated secondary antibod-
ies and developed with enhanced chemiluminescence (ECL)
reaction (Amersham-Pharmacia-Biotech).
In situ nuclear matrix preparation
Unfixed fibroblast cultures were washed in PBS, treated
with a buffer containing 10 mM Tris-HCl (pH 7.4), 150 mM
NaCl, 5 mM MgCl2, 1% NP-40, 1 mM PMSF, 10 g/ml
leupeptin, and aprotinin for 15 min at room temperature.
Detergent-treated cells were washed twice in the absence of
NP-40, subjected to DNase treatment (20 U/ml for 1 h at
room temperature) and high salt extraction in 2 M NaCl
containing buffer for 5 min at room temperature. This treat-
ment led to complete removal of chromatin (as demon-
strated by the absence of DAPI staining of nuclei, not
shown). Samples were fixed with 2% paraformaldehyde and
processed for immunofluorescence labeling.
In situ transcription
Living fibroblasts were treated according to published
protocols [26]. Briefly, cells were permeabilized in a buffer
containing 20 mM Tris-HCl (pH 7.4), 5 mM MgCl2, 0.5
mM EGTA, 25% glycerol, 10 g/ml digitonin, 1 mM
PMSF, RNasin (20 U/ml). Transcription assay was per-
formed for 5 min in a buffer containing 50 mM Tris-HCl,
pH 7.4, 100 mM KCl, 10 mM MgCl2, 0.5 mM EGTA, 25%
glycerol, 2 mM ATP, 0.5 mM CTP, 0.5 mM GTP, 0.5 mM
BrUTP, 1 mM PMSF and RNasin (20 U/ml) (Promega).
-Amanitin (10 g/ml) (Sigma) was added to the transcrip-
tion buffer to obtain negative controls (not shown). Cells
were washed in PBS and fixed in 2% paraformaldehyde at
room temperature. Incorporated nucleotides were revealed
by immunofluorescence labeling with anti-BrdU antibody.
Chromatin was counterstained with 4,6-diamidino-2-phe-
nylindole (DAPI, 0.1 g/ml) (Sigma).
Immunofluorescence
Fibroblasts grown on coverslips were fixed with metha-
nol at 20°C or with 2% paraformaldehyde at 4°C. Para-
formaldehyde-fixed fibroblasts were permeabilized with
0.15% Triton X-100 in PBS. All preparations were incu-
bated with PBS containing 4% BSA to saturate nonspecific
binding. Incubation with primary antibodies was performed
overnight at 4°C, while secondary antibodies were applied
for 1 h at room temperature. Slides were mounted with an
antifade reagent in glycerol and observed with a Nikon E
600 fluorescence microscope equipped with a digital cam-
era.
Electron microscopy
FPLD fibroblasts and controls were fixed with 2.5%
glutaraldehyde–0.1 M phosphate buffer, postfixed with 1%
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OsO4 in veronal buffer, dehydrated in ethanol, scraped, and
embedded in epoxy resin. Ultrathin sections were cut from
two different embedded blocks of mutated and control cells,
respectively, counterstained with uranyl acetate-lead citrate,
and observed with a Philips EM 400 T electron microscope,
operated at 100 KV. For each sample, about 250 nuclei were
evaluated.
Results
Lamin A and emerin do not interact in cell lysates from
FPLD R482L fibroblasts
Lamin A/C has been demonstrated to bind directly
emerin [20]. This interaction has been shown to involve
mainly lamin A as for the strength of binding [21]. It
depends mostly on lamin A for retaining emerin at the
nuclear envelope [23]. The sequence that binds emerin in-
cludes amino acids 384 to 566 [21] in the tail domain shared
by lamins A and C. Since the mutated FPLD sequence is
within this domain, we immunoprecipitated FPLD fibro-
blast lysates with anti-emerin antibody to check if emerin-
lamin binding was affected by the R482L mutation. An
immunoblot of the immunoprecipitated complex showed
that lamin A failed to coprecipitate with emerin in these
cells (Fig. 1), while the two proteins coprecipitated in con-
trol fibroblasts as well as in EDMD2 fibroblasts cultured
under the same conditions (Fig. 1). On the contrary, lamin
C was still bound to emerin in FPLD fibroblasts (Fig. 1).
The amount of both lamin A and C was not affected in the
whole cell lysates from FPLD fibroblasts suggesting that the
proteins are expressed at normal levels (Fig. 1). Moreover,
the emerin-immunoblotted band was not reduced in FPLD
whole cell lysates with respect to controls (Fig. 1). As
expected, immunoprecipitation of lamin A/C from FPLD
fibroblasts with an anti-lamin A/C monoclonal antibody
allowed us to detect coprecipitation of emerin (Fig. 1), thus
demonstrating that the interaction between emerin and
lamin A/C is preserved through lamin C binding.
Lamin A/C distribution is dramatically affected in FPLD
R482L fibroblasts
To check lamin A/C distribution in cultured FPLD fibro-
blasts we immunolabeled methanol or paraformaldehyde
fixed cells with anti-lamin A/C (Fig. 2). Nuclear lamina
staining was observed in 80% of labeled fibroblasts, while a
marked reduction of labeling was observed at the nuclear
rim in 15–20% of FPLD cells (338 out of 1890 nuclei), with
lamin A/C being mainly distributed into nuclear aggregates
(Fig. 2A). The same pattern of distribution was observed
with an anti-lamin A antibody (not shown). The number of
nuclear lamin A/C aggregates varied from 10 to 30 per
nucleus and the aggregates appeared to be uniformly dis-
tributed throughout the nuclei (Fig. 2). Lamin A/C aggre-
gates were not observed in control fibroblasts (Fig. 2).
We immunolabeled the same samples with anti-lamin B2
antibody and found that lamin A and lamin B2 colocalized
in some, but not all the intranuclear aggregates (Fig. 2). This
finding suggests that partial redistribution of lamin B in
these FPLD fibroblasts does occur. In addition, alterations
of the lamin A/C lattice (Fig. 2B) were observed in about
15% of fibroblasts as compared with only 4% in controls
and 10% in EDMD2 fibroblasts (Fig. 3). In FPLD cells,
lamin A/C was irregularly organized at one pole of the
nucleus, with a sponge-like appearance, and lamin B2 was
absent from the same area (Fig. 2B). This finding is in
agreement with data reported by Vigouroux et al. [24].
Interestingly, in 3.5% of fibroblasts we could observe both
these lamina abnormalities and the presence of lamin A/C
aggregates (Fig. 2B). It is conceivable that both defects
result from impaired interaction of lamin A/C with other
nuclear binding partners.
Emerin is not detected at nuclear lamin A/C aggregates
Lamin A/C aggregates were not observed in control
fibroblasts from either unaffected controls or EDMD2 pa-
tient carrying R401C LMNA mutation (Fig. 3A). We won-
dered if emerin was still retained at the nuclear envelope in
R482L FPLD fibroblasts or if it was relocalized due to the
lack of binding to lamin A as observed by immunoprecipi-
tation (Fig. 1A) or as a consequence of the apparent mislo-
calization of lamin A/C. Double immunofluorescence label-
ing using antibodies against lamin A/C and emerin (Fig. 3)
showed that emerin localization was not affected in FPLD
fibroblasts compared to control fibroblasts (Fig. 3), while
the intensity of emerin staining appeared slightly reduced in
cells bearing the lamin A/C aggregates (Fig. 3). In EDMD2
fibroblasts lamin A/C aggregates were not found, while
nuclear lamina holes and thickening of the nuclear rim were
observed (Fig. 3). In FPLD cells, emerin was never detected
at the lamin A/C aggregates (Fig. 3). Double labeling of
emerin and lamin A/C also allowed us to define the exact
localization of lamin A/C aggregates observed in FPLD
fibroblasts. As also shown in Fig. 3, the aggregates are not
visible in the equatorial plane of the nucleus, i.e., they are
mostly localized close to the nuclear lamina.
Peripheral heterochromatin distribution is altered in
FPLD nuclei
Electron microscopy of FPLD fibroblast nuclei showed
an altered distribution of peripheral chromatin in a high
percentage of nuclei (about 20%, 53 nuclei out of 250
observed) compared to controls (no alterations detected)
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(Fig. 4). Lack of heterochromatin was observed at the nu-
clear periphery, close to the nuclear lamina (arrows); in
these areas the nucleoplasm appeared less electron dense
than normal (Figs. 4A and C); nuclear pores were generally
absent in the areas corresponding to the peripheral hetero-
chromatin loss (Fig. 4D). Detachment of chromatin from the
nuclear lamina was also observed (arrowhead Fig. 4A).
Neither thickening of the nuclear lamina nor nuclear enve-
lope breaches were detected. These observations indicate
that altered organization of the nuclear lamina can affect the
chromatin arrangement. This is consistent with previously
published data demonstrating altered chromatin organiza-
tion in EDMD cells and muscle tissue bearing lamin A/C
[34] or emerin [35] mutations.
Fig. 5. Lamin A/C aggregates partially colocalize with intranuclear lamin A/C sites and splicing factor components. (A) Anti-lamin A (2H10) antibody was
used to label intranuclear lamin A foci in control and FPLD fibroblasts. 2H10-labeled sites, mostly, did not colocalize with lamin A/C aggregates of R482L
FPLD cells. However, in a minor percentage the aggregates colocalized with internal lamin A foci (arrowhead). (B) Antisplicing factor SC35 antibody
staining allowed us to demonstrate that redistribution of splicing sites by okadaic acid treatment does not affect lamin A/C aggregates. SC35 and lamin A/C
were double-labeled in control fibroblasts and in R482L FPLD fibroblasts before and after okadaic acid treatment. Bar, 2.4 m for (A) and 10 m for (B).
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Lamin A/C aggregates do not correspond to intranuclear
lamin A/C sites
Intranuclear lamin A foci have been previously described
in G1 cells [31] and also in interphase cells by labeling with
a specific antibody [33]. We wondered if lamin A/C aggre-
gates observed in FPLD fibroblast nuclei could correspond
to intranuclear structures observed in normal cells and could
be detected in FPLD cells better than in control fibroblasts
due to epitope unmasking.
Immunolabeling of FPLD fibroblasts was performed
with the 2H10 antibody, which selectively binds to lamin A
at intranuclear sites [33]. In most nuclei, the lamin A/C
aggregates detected by anti-lamin A/C antibody did not
colocalize with 2H10 labeled sites (Fig. 5). It should be
noted that intranuclear lamin A foci are found throughout
the nucleus (except the nucleolus) whereas the abnormal
aggregates are mostly localized toward the nuclear periph-
ery. However, in a lower percentage of cells, the two fluo-
rescence signals partially coincided (Fig. 5). This finding
suggests that the abnormal distribution of lamin A/C in
FPLD fibroblasts could represent an alteration of a dynamic
situation, at least in part involving intranuclear lamin A foci.
To check if lamin A/C aggregates were structurally or
functionally related to intranuclear lamin A/C foci known to
be associated with mRNA splicing compartments, we
treated FPLD fibroblasts with okadaic acid. Okadaic acid is
a phosphatase inhibitor known to cause redistribution of
splicing factor SC35 and of several components of the
splicing factor complexes [36]. As shown in Fig. 5, SC35
was redistributed after okadaic acid incubation, but lamin
A/C aggregates were not affected by the treatment. Thus,
we can conclude that the nuclear aggregates do not corre-
spond to lamin A/C-containing structures present inside the
nucleus in normal cells [33], but represent abnormal struc-
tures that form close to the nuclear lamina as a consequence
of R482L lamin A/C mutation.
The lamin A/C aggregates observed in FPLD nuclei were
not extracted by detergent treatment and were still detect-
able after DNase digestion and high salt extraction (Fig. 6),
thus suggesting that they were bound to the nuclear matrix.
The presence of lamin A/C aggregates is increased in G1
and G2 cells
To rule out the possibility that mutated lamin A/C could
interfere with cell cycle progression, fluorescence-activated
cell-sorting analysis (FACS analysis) of cultured FPLD
fibroblasts was performed. A distribution of the FPLD fi-
broblast population in the cell cycle phases comparable to
that observed in control fibroblasts was detected (not
shown).
Immunofluorescence labeling with anti-lamin A/C anti-
body was then performed on synchronized FPLD fibro-
blasts, to evaluate the rate of lamin A/C aggregate formation
in the different cell cycle phases. Fibroblasts synchronized
in the G1 phase by serum starvation and release or in the G2
phase by demecolcine treatment showed increased lamin
A/C aggregates with respect to nonsynchronous FPLD cells
(Fig. 7). In addition, starved cells obtained after 7 days of
serum deprivation, completely lost lamin A/C aggregates.
We did not observe any lamin A/C aggregates in S phase
cells (as determined by proliferating cell nuclear antigen
(PCNA) and lamin A/C double staining of asynchronous
Fig. 6. Double staining of emerin and lamin A/C was performed in in situ
nuclear matrix preparations. FPLD fibroblasts carrying lamin A/C aggre-
gates show a slightly reduced emerin staining at the nuclear rim. In FPLD
nuclei, lamin A/C aggregates are bound to the nuclear matrix after DNase
treatment and high salt extraction. Bar, 10 m.
Fig. 7. Increased nuclear lamin A/C aggregates in G1 cells. The nuclear
aggregates are not detected in G0 fibroblasts and in S-phase cells. Control
(C) and mutant R482L (FPLD) fibroblasts were synchronized as described
in Materials and methods and double-stained with lamin A/C and PCNA to
detect cells in different phases of the cell cycle. In G1 cells the percentage
of nuclei with lamin aggregates was 35% (out of 1500 examined). Starved
cells (starved) were obtained after 7 days of serum depletion and treated
with 10 M insulin for 4 h (insulin). In insulin-treated fibroblasts 32% of
nuclei (out of 1320 examined) showed lamin aggregates. The mean of the
results of three different counts performed in different samples /
standard deviation are reported per each point. (NS, not synchronous; G1,
G1 phase; S, S phase; G2, G2 phase; G0, G0 phase.)
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cells, not shown). Thus, abnormal lamin A/C structures did
not occur in G0 cells or, alternatively, in cells with low
transcriptional activity. This finding suggests that formation
of lamin A/C aggregates is a failure of correct lamin A/C
assembly into a functionally active structure. This hypoth-
esis is supported by the observation that insulin treatment of
serum-depleted FPLD cells raised to 32% the percentage of
nuclei bearing lamin A/C aggregates (Fig. 7).
Transcriptional activity is altered in FPLD R482L
fibroblasts
To check whether abnormal lamin A/C organization
could interfere with RNA polymerase II activity, we per-
formed an in situ transcription assay that allowed us to
determine the relative amount of incorporated bromouridine
(BrU) into transcribed RNA. A bright punctate staining was
observed in the nuclei of control fibroblasts (Fig. 8A) and in
FPLD nuclei with normal lamin A/C organization at the
nuclear lamina. In all FPLD fibroblasts bearing abnormal
lamin A/C aggregates (15–20% of the total population) we
found strongly reduced incorporation of BrU as determined
by immunofluorescence (Fig. 8B). These findings demon-
strate that the R482L mutation of LMNA, which causes
FPLD, interferes with RNA polymerase II-mediated tran-
scription. In fact, in cells showing complete absence of BrU
fluorescence in the nucleoplasm, nucleolar staining was
often observed (not shown), suggesting that RNA polymer-
ase I-mediated transcription is not affected. It should be
noted that DAPI staining of nuclei (Fig. 8A) allowed us to
rule out the possibility that BrU-negative nuclei were apo-
ptotic: in fact, neither hypercondensed chromatin nor mi-
cronuclei were found in fibroblasts showing reduced tran-
scriptional activity.
Discussion
The overall evaluation of our results shows that:(1) mu-
tation of lamin A/C at R482 affects interaction of the nu-
clear lamina protein with both nuclear envelope (emerin)
and nuclear lamina (lamin B2) components; (2) in R482L
FPLD fibroblasts, lamin A/C is redistributed in a significant
percentage of nuclei and an altered nuclear lamina assembly
is observed mostly in G1 and G2 cells, but not in G0
fibroblasts; (3) in FPLD fibroblast nuclei, altered hetero-
chromatin distribution close to the nuclear lamina occurs
and heterochromatic areas are frequently lacking; (4) the
lamin A/C aggregates observed in FPLD fibroblasts are not
bound to DNA or splicing factor compartments, but a low
percentage of aggregates colocalize with intranuclear lamin
A sites; (5) a reduced RNA transcription rate is observed in
FPLD nuclei carrying lamin A/C aggregates, as determined
by in situ transcription assay.
R482L lamin A/C mutation causes disruption of lamin
organization
In FPLD fibroblast nuclei carrying an R482L mutation of
lamin A/C, we observed the formation of lamin A/C aggre-
gates localized close to the nuclear lamina. This abnormal
distribution of lamin A/C has never been observed before in
FPLD nuclei and can be strictly related to the amino acid
substitution present in these cells. An altered organization of
lamin A/C, similar to the one observed in this study, has
been described by Lloyd et al.[28] in HeLa cells transiently
transfected with an E203G lamin A/C mutation, which is
associated with dilated cardiomyopathy (CMD1A). These
authors suggest that the E203G LMNA mutation can affect
the self-assembly of the molecule, thus causing formation of
intranuclear aggregates [28]. In R482L FPLD fibroblasts, it
is more probable that the amino acid substitution may affect
an interaction with other nuclear partner(s) [28,37] neces-
sary for proper nuclear lamina organization. The nuclear
lamin A/C aggregates present in R482L FPLD fibroblasts
represent anomalous lamin A/C structures not anchored to
nuclear components involved in either DNA replication or
RNA splicing. Thus, it appears likely that the lamin A/C
aggregates observed in FPLD R482L fibroblasts are formed
as a consequence of lacking functional interaction usually
occurring in normal fibroblasts. The variable impact on the
lamina structure of R482L lamin A/C mutation can be
explained by hypothesizing that a functional interaction
occurring in a percentage of an asynchronous cell popula-
tion may be impaired in FPLD fibroblasts. This hypothesis
is supported by the fact that accumulation of cells in G1, as
well as insulin treatment, increase the rate of altered nuclei.
The latter is an intriguing result, suggesting that some post-
translational modification of lamin A/C, such as phosphor-
ylation, may occur in the nuclei with altered lamin A/C
distribution. On the other hand, insulin signaling plays a
major role in adipocyte differentiation through the
SREBP1-PPAR pathway [38]: thus, lamin A/C distribu-
tion in response to insulin stimulus should be investigated in
an adipocyte cellular model, and intermolecular interactions
between lamin A/C and its possible partner protein SREBP1
[28] or chromatin [39] should be evaluated.
R482L mutated lamin A fails to interact with emerin
Moreover, we demonstrate that lamin A fails to bind
emerin in FPLD R482L fibroblasts, while lamin C, whose
interaction with emerin is not disrupted, is sufficient to
retain the nuclear envelope protein at its proper localization.
The finding that lamin A and emerin do not coprecipitate in
R482L FPLD fibroblasts was an unexpected finding. Other
authors reported that the interaction between emerin and
lamin is not affected in FPLD fibroblasts carrying different
mutations [24,40] or in in vitro pull-down assays performed
with lamin A/C R482W mutant [41]. We suggest that a
different amino acid substitution (R482L instead of
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R482Q/W) [24,37,41] elicits different effects on the inter-
molecular interactions involving the mutated C-terminal
domain. In this respect, it is noteworthy that an Ig-like
domain has been recently identified in the carboxy-terminal
globular domain of lamin A, which has been suggested to be
involved in intermolecular interactions [37,42]. Moreover,
loss of a basic side chain at the carboxy-terminus of lamin
A/C has been demonstrated in FPLD cells [37]. Thus, we
hypothesize that the presence of a nonpolar amino acid such
as leucine within this domain impairs lamin A–emerin bind-
ing. Another explanation for the failure of emerin to bind
lamin A could be the absence of an interaction with a third
molecule necessary to stabilize the emerin-lamin A com-
plex. In fact, other interactions with lamin A/C could also be
altered in nuclei carrying the R482L mutation and thus elicit
a pathogenic effect. As far as the site of interaction between
LAP2 and lamin A/C is within the mutated C-terminal
domain of lamin A/C [29], the interaction with LAP2 is
possibly also interrupted in R482L FPLD. Reduced in vitro
binding of lamin A/C mutants found in FPLD to the sterol
response element binding protein 1 (SREBP1) has been
recently demonstrated [28]. The evidence of impaired emer-
in–lamin A binding as reported in this study represents the
first evidence of altered in vivo protein–protein interaction
in FPLD cells. This supports the hypothesis of a major role
of abnormal lamin A interference with its partner protein(s)
in the pathogenesis of FPLD [37].
Chromatin disorganization is a common feature of
laminopathies
We previously described altered lamin distribution in
EDMD1 fibroblasts [35] and altered chromatin organization
in both EDMD1[35] and EDMD2 fibroblasts [34]. A mark-
edly altered heterochromatin arrangement and areas devoid
of heterochromatin have been observed also in FPLD fibro-
blasts (Fig. 4). This observation was not unexpected, since
not only lamin A/C is mutated in FPLD, but also emerin-
lamin A binding is impaired in R482L FPLD cells: thus, a
nuclear envelope defect is again found to be associated with
altered chromatin organization. This finding suggests that a
common mechanism leading to chromatin disorganization
may underlie the pathology caused by nuclear envelope–
nuclear lamina defects [43]. This hypothesis is strongly
supported by a recent report by Stierle´ et al. [39] demon-
strating that the lamin A/C sequence around the amino acid
R482 contains a DNA-binding domain that allows a stable
DNA interaction in cooperation with the NLS-containing
peptide [39]. Interestingly, these authors further show that
no DNA sequence specificity is required for lamin A/C
binding, again suggesting that lamin A/C could be involved
in a more general mechanism regulating chromatin organi-
zation.
Blebbed areas lacking lamin B were recently described
in FPLD fibroblasts carrying different amino acid substitu-
tions by Vigouroux et al. [24]. Also, these authors showed
that transfection of normal fibroblasts with a vector encod-
ing an R482W mutated lamin A/C causes in a percentage of
nuclei an altered lamin A/C organization with holes and
lack of lamin B in the same areas [24]. This finding is
consistent with our results obtained with R482L FPLD
cells.
Mutated R482L lamin A/C can affect RNA transcription
Further evidence to the hypothesis that nuclear lamin
A/C aggregates are formed due to the lack of a normal
functional interaction is given by the finding that the nuclear
aggregates are not found in serum-starved cells, while their
frequency increases in G1 and G2 fibroblasts. Thus, the
aggregates must correspond to anomalous lamin A/C struc-
tures forming in actively transcribing cells. It is noteworthy
that lamin A/C aggregates were not observed in S-phase
cells, so that we can rule out that they represent a failure of
lamin A/C to correctly assemble into structures involved in
DNA replication. On the basis of these results, we further
evaluated the transcriptional activity of R482L FPLD cells.
Involvement of nuclear envelope proteins in the regulation
of gene expression has been demonstrated for LAP2 beta
and its associated germ-cell-less protein [44]. Moreover, a
report by Spann et al. [26] shows that a mutated lamin A
impairs RNA polymerase II-mediated transcription in trans-
fected cells. Our results agree with those of Spann et al.
[26], as far as we demonstrated a reduced BrU incorporation
in R482L-mutated nuclei bearing lamin A/C aggregates.
This finding provides the first evidence that RNA transcrip-
tion is affected in a laminopathy, concomitantly with failure
of lamin A/C to correctly assemble at the nuclear lamina. It
is noteworthy that the presence of lamin A/C aggregates in
FPLD nuclei appears to be dependent on the functional
status of the cell (cells accumulated in G1 showed aggre-
gates to a higher percentage). Thus, virtually all FPLD
fibroblasts could undergo an alteration of lamin A/C ar-
rangement, and as a consequence an altered RNA transcrip-
tion rate, under a determined functional condition. Lamin
A/C has been shown to interact with SREBP1 [28] as well
as with MOK2 transcription factor and to affect the nuclear
localization of the latter [45]. Concerning the diseases as-
sociated with nuclear envelope defects, a recent expression
profiling in EDMD1 cells using cDNA microarray analysis
showed altered expression of several genes, including
LMNA [46]. Thus, altered gene expression in laminopathies,
as previously speculated by several authors [16,43,47], is
now gaining experimental evidence. Nevertheless, more
than one mechanism is likely to be involved in the patho-
genesis of laminopathies [48], and proved and potential
nuclear binding partners of lamins may be linked to the
pathogenetic mechanism. In this respect, it is worthy to note
that a transactivation-deficient mutant of PPARG encoding
peroxisome proliferator activated receptor (PPAR)- has
been recently identified in a FPLD not linked to LMNA
mutation [49]. The analysis of the in vivo interaction be-
131C. Capanni et al. / Experimental Cell Research 291 (2003) 122–134
tween lamin A/C and PPAR- or SREBP1 [28] could give
an insight into the altered mechanism leading to FPLD.
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